Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

10.85EUR
18 Oct 2018
Change (% chg)

€-0.18 (-1.63%)
Prev Close
€11.03
Open
€11.11
Day's High
€11.27
Day's Low
€10.85
Volume
97,940
Avg. Vol
163,740
52-wk High
€19.42
52-wk Low
€9.86

Latest Key Developments (Source: Significant Developments)

Medigene AG Says Raised 32.3 Mln EUros In Oversubscribed Private Placement
Thursday, 24 May 2018 

May 24 (Reuters) - Medigene AG ::MEDIGENE SUCCESSFULLY RAISES EUR 32.3 MILLION IN OVERSUBSCRIBED PRIVATE PLACEMENT.ISSUED 2,230,000 NEW SHARES FROM AUTHORIZED CAPITAL, REPRESENTING APPROXIMATELY 10% OF CURRENTLY OUTSTANDING SHARES.SHARES WERE ALLOCATED TO INSTITUTIONAL INVESTORS AT A PRICE OF EUR 14.50 PER SHARE.FINANCING WILL INCREASE TOTAL NUMBER OF REGISTERED SHARES TO 24,544,595.  Full Article

Germany's Medigene AG announces capital increase
Thursday, 24 May 2018 

May 24 (Reuters) - Medigene AG ::SAYS MEDIGENE AG - MEDIGENE ANNOUNCES CAPITAL INCREASE TO FUND IMMUNOTHERAPY PROGRAMS.SAYS EXPECTS TO ISSUE UP TO 2.23 MILLION NEW SHARES FROM AUTHORIZED CAPITAL, WHICH REPRESENTS APPROXIMATELY 10% OF CURRENTLY OUTSTANDING SHARE CAPITAL..  Full Article

Medigene Affirms FY Guidance
Wednesday, 9 May 2018 

May 9 (Reuters) - Medigene AG ::Q1 REVENUES UP 6 PERCENT AT 2.77 MILLION EUROS.Q1 EBITDA LOSS WIDENS BY 6 PERCENT TO 3.19 MILLION EUROS.AFFIRMS FY GUIDANCE FOR EBITDA LOSS OF 21 - 23 MILLION EUROS.SAYS HAS SUFFICIENT RESOURCES TO FUND BUSINESS OPERATIONS BEYOND THE PLANNING HORIZON OF 2 YRS.  Full Article

Medigene Sells US-Rights For Veregen, Raises 2017 Guidance
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - MEDIGENE AG ::PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017.EXPECTS REVENUES OF EUR 10.5-11.5 M INSTEAD OF EUR 8-10 M AS PREVIOUSLY GUIDED.EXPECTS 2017 EBITDA-LOSS OF EUR 14-15 M INSTEAD OF EUR 16-18 M.EXPECTS 2017 CASH UTILIZATION OF EUR 20-22 M INSTEAD OF EUR 23-27 M.  Full Article

Medigene says 9M immunotherapy revenue 3.4 mln eur
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Medigene :Says confirms its financial guidance for 2017.Says 9M revenue from core business immunotherapies (bluebird bio partnership) of eur 3.435 million.Says 9M total revenue eur 7.176 million (9M 2016: eur 7.052 million).Says 9M EBITDA loss increased as planned to eur 10.143 million (9M 2016: eur 9.095 million).  Full Article

German stocks - Factors to watch on Sept. 24

FRANKFURT/BERLIN, Sept 24 The following are some of the factors that may move German stocks on Monday: